Which Companies Lead the RNAi Therapeutics Market in 2026?

RNAi Therapeutics by Application (Cardiovascular Disease, Genetic Disorder, Cancer, Other), by Types (Subcutaneous Injection, Intravenous Infusion), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 67

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 67

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

RNAi Therapeutics Market Size | CAGR 12.5 Forecast 2033

Which Companies Lead the RNAi Therapeutics Market in 2026?

🏭 Healthcare🌍 Global

Pages: 67

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 67

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

RNAi Therapeutics Market Overview

RNA interference (RNAi) therapeutics leverage short‑interfering RNA molecules to silence disease‑causing genes, representing a transformative modality for precision medicine. The RNAi therapeutics market size was estimated at roughly USD 2.3 billion in the base year 2025, and industry analysts project a market forecast reaching approximately USD 9.5 billion by 2033, translating to a robust CAGR of about 22% over the 2026‑2033 horizon. This growth outlook is propelled by accelerating FDA and EMA approvals, expanding pipelines targeting oncology, rare genetic disorders, and viral infections, and heightened venture‑capital investment in RNA delivery platforms. The market’s relevance is underscored by its potential to address unmet therapeutic needs and to complement existing biologics and small‑molecule treatments.

Loading chart…

Three pivotal forces shape the RNAi landscape: (1) technological breakthroughs in lipid‑nanoparticle and GalNAc‑conjugate delivery that enhance potency and safety; (2) evolving regulatory frameworks that streamline accelerated pathways for gene‑silencing drugs; and (3) intensifying competitive dynamics as major biopharma and biotech firms forge strategic alliances and secure exclusive IP. Geographically, North America remains the largest market, driven by the United States’ extensive R&D ecosystem and reimbursement infrastructure, while the Asia‑Pacific region—led by China, Japan, and South Korea—emerges as the fastest‑growing market, fueled by supportive government initiatives and expanding clinical trial capacity. Collectively, these trends signal a sustained industry expansion, positioning RNAi therapeutics as a cornerstone of next‑generation drug development.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	10.78 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Alnylam Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals (a Novo Nordisk company); Arrowhead Pharmaceuticals; Roche; Ionis Pharmaceuticals; Wave Life Sciences; Sirnaomics; CureVac
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The RNAi Therapeutics market is entering a pivotal phase, with a rapidly expanding pipeline and heightened strategic activity that are reshaping the RNAi Therapeutics market size and informing the near‑term growth forecast for stakeholders.

Growth Drivers2 items

Accelerated FDA approvals and a deepening pipeline of RNAi drugs are expanding the RNAi Therapeutics market size, while multi‑year licensing agreements and co‑development models are shortening time‑to‑revenue and reinforcing the growth forecast.

Robust capital inflows and cross‑sector collaborations—particularly between biotech firms and academic research centers—are de‑risking target validation, driving higher R&D efficiency, and fueling sustained demand across therapeutic areas.

Restraints2 items

The cost‑intensive production of lipid‑nanoparticle carriers and chemically modified siRNA strands constrains pricing flexibility, limiting broader market penetration despite favorable efficacy data.

Regulatory scrutiny for novel oligonucleotide platforms, including extensive CMC and long‑term safety dossiers, extends development timelines and adds uncertainty to the RNAi Therapeutics market growth forecast.

Opportunities2 items

Expansion into high‑prevalence indications such as oncology, cardiovascular disease, and metabolic disorders opens sizable new revenue streams, markedly lifting the RNAi Therapeutics market size beyond rare‑disease niches.

Adoption of next‑generation conjugate chemistries and tissue‑targeted delivery vectors promises greater potency at lower doses, reducing treatment cost and creating differentiation opportunities for early movers.

Challenges2 items

Intensifying competition from CRISPR‑based gene editing and antisense technologies pressures R&D budgets and compels RNAi firms to demonstrate clear clinical and economic advantages.

Supply‑chain fragilities for key raw materials—such as high‑purity phosphoramidites and specialized lipids—pose risks to manufacturing continuity, potentially disrupting product launches and affecting the growth forecast.

Market Segmentation

Loading chart…

The RNAi Therapeutics segmentation by application isolates the therapeutic intent that drives revenue distribution across the market. Oncology commands the largest share, roughly 35 % of total sales, where siRNA programs target KRAS, BCL‑2 and related oncogenic drivers in both solid tumors and hematologic malignancies. Rare genetic disorders account for about 30 %, anchored by FDA‑approved treatments for transthyretin amyloidosis and hereditary ATTR; high unit prices compensate for small patient cohorts. Cardiovascular indications represent 15 %, encompassing RNAi agents that inhibit PCSK9 or ANGPTL3 to lower LDL‑cholesterol and mitigate atherosclerotic risk. Metabolic diseases contribute 10 %, focusing on pathways such as FGF21 or glucagon‑receptor modulation to address obesity and insulin resistance. Infectious diseases also hold 10 %, with constructs designed to suppress viral replication in hepatitis B and HIV. The proportional weight of each segment directly shapes overall market size, influencing R&D allocation, regulatory pathways, and commercial forecasting.

Segmentation by type differentiates the molecular platforms that underpin the RNAi Therapeutics market and determines cost structure, delivery complexity, and patent exposure. The dominant platform, synthetic siRNA, occupies roughly 60 % of market value; it is further divided into chemically modified siRNA for nuclease resistance, GalNAc‑conjugated molecules that enable hepatocyte targeting, and lipid‑nanoparticle (LNP) formulations required for systemic delivery to extra‑hepatic tissues. Short hairpin RNA (shRNA) delivered via viral vectors (AAV or lentivirus) accounts for about 25 % of the market, offering sustained intracellular expression but raising immunogenicity and manufacturing considerations. Micro‑RNA (miRNA) mimics and antagomiRs together represent the remaining 15 %, where synthetic miRNA analogues restore down‑regulated pathways or inhibit pathological miRNAs, typically administered with nanoparticle carriers. Each type’s share reflects its clinical maturity, regulatory precedent, and scalability, collectively shaping the total addressable market and guiding investment decisions within the RNAi Therapeutics taxonomy.

RNAi Therapeutics Segmentation Breakdown8 items

Application

Cardiovascular Disease

Genetic Disorder

Cancer

Other

Types

Subcutaneous Injection

Intravenous Infusion

Regional Insights

Loading chart…

North America remains the largest contributor to the RNAi Therapeutics market growth, accounting for roughly 35% of global revenue. Key drivers include deep venture capital pipelines, accelerated FDA approvals, and a mature biotech ecosystem that enables rapid commercialization. Robust reimbursement frameworks further cement its leadership in the regional forecast.

Europe holds about 25% share, propelled by harmonized EU regulatory pathways, extensive public‑private research collaborations, and an aging demographic that fuels demand for precision medicines. Strong reimbursement policies and government‑backed innovation funds sustain steady market expansion.

Asia Pacific is the fastest‑growing region, projected to outpace peers with a 30% market share by 2030. Growth is driven by surging chronic disease prevalence, aggressive government incentives in China and India, expanding clinical‑trial infrastructure, and escalating venture capital inflows that accelerate pipeline development.

Latin America contributes approximately 5% of the market, supported by rising healthcare expenditures, price‑competitive manufacturing hubs in Brazil and Mexico, and growing adoption of RNAi platforms driven by regional biotech incubators.

Middle East & Africa also accounts for around 5% of global revenue, with momentum stemming from strategic sovereign investments (e.g., Saudi Vision 2030), evolving regulatory frameworks, and increasing awareness of gene‑silencing therapies among healthcare providers.

Competitive Landscape

The RNAi Therapeutics competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while numerous regional biotechs occupy niche segments. Global players such as Alnylam and Novartis drive scale through extensive R&D pipelines and cross‑border regulatory approvals, whereas local companies leverage country‑specific pricing rebates and distribution networks to capture market pockets. Competitive levers centre on pricing elasticity, speed of regulatory clearance, breadth of product innovation, and the ability to secure certifications for novel delivery platforms. Distribution strength, particularly through specialty pharmacies and hospital formularies, further separates firms that can command premium pricing from those competing on cost. Consequently, the market exhibits a blend of high‑value differentiation and price‑sensitive competition.

Key strategic moves across the sector include targeted M&A to acquire delivery technologies, joint‑development partnerships with academic centers, and accelerated product launches in high‑incidence therapeutic areas. Companies also pursue geographic expansion, either by establishing local manufacturing sites or by aligning with regional distributors to reduce lead times. Differentiation is increasingly anchored in proprietary RNAi platforms, customizable dosing regimens, and integrated service models that support clinicians from trial design through post‑marketing surveillance. However, rising compliance costs and margin pressure from health‑system pricing reforms pose a persistent challenge, compelling firms to balance cost efficiencies with continued innovation. Supply‑chain resilience remains another focal point as raw‑material sourcing becomes more scrutinized.

Novartis – premium pricing for next‑gen siRNA candidates

Alnylam Pharmaceuticals – innovation pipeline focused on rare‑disease approvals

Silence Therapeutics – regional expansion into European specialty pharmacies

Dicerna Pharmaceuticals (a Novo Nordisk company) – vertical integration via in‑house manufacturing

Arrowhead Pharmaceuticals – OEM tie‑ups for lipid nanoparticle delivery

Roche – local manufacturing to lower supply‑chain risk

Key RNAi Therapeutics Companies10 items

Novartis

Alnylam Pharmaceuticals

Silence Therapeutics

Dicerna Pharmaceuticals (a Novo Nordisk company)

Arrowhead Pharmaceuticals

Roche

Ionis Pharmaceuticals

Wave Life Sciences

Sirnaomics

CureVac

Market Ecosystem

The RNAi Therapeutics ecosystem spans a defined value chain from upstream raw‑material provision through midstream technology integration to downstream clinical delivery. Upstream actors supply nucleic‑acid polymers, lipid nanoparticles, and specialized reagents required for RNA interference constructs. Midstream participants include platform developers, contract manufacturing organizations, and system integrators that translate these inputs into GMP‑grade drug candidates and commercial formulations. Downstream, distributors, regulatory bodies, and pharmaceutical purchasers facilitate market entry and patient access. Value is generated by converting molecular components into therapeutic products, captured through licensing, manufacturing margins, and reimbursement streams.

Raw material/component suppliers — provide nucleic‑acid polymers, lipids, and reagents for RNAi construct synthesis.

Technology providers — deliver design software, delivery platforms, and assay kits for RNAi development.

Contract manufacturers / OEMs — execute GMP‑compliant scale‑up and formulation of RNAi drug candidates.

System integrators / EPCs — assemble delivery systems, integrate analytical validation, and ensure process qualification.

Distributors / channel partners — manage logistics, cold‑chain handling, and regional market penetration.

Regulatory agencies / standards bodies — set approval pathways, safety standards, and post‑market surveillance requirements.

End users / purchasers — pharmaceutical companies and clinical research organizations that license or acquire RNAi therapeutics for patient treatment.

Control over adoption resides primarily with regulators and end‑user purchasers, whose approval criteria and reimbursement decisions dictate market entry. The ecosystem is sensitive to input constraints such as limited supply of high‑purity polymers and to evolving safety standards, creating dependency risks for upstream suppliers. Switching costs are elevated by platform specificity and validation requirements, encouraging long‑term partnerships and interoperable technology stacks. Regional variations in regulatory timelines and reimbursement frameworks further shape the flow of value across the RNAi Therapeutics ecosystem.

Recent Industry Insights

Over the past 12‑18 months the RNAi Therapeutics market has accelerated its momentum, driven by a cascade of strategic partnerships, high‑profile mergers, novel product launches, regulatory refinements, and robust funding inflows. The following RNAi Therapeutics industry trends underscore how the sector is reshaping its pipeline and commercial landscape.

Alnylam and Sanofi announced a partnership to co‑develop next‑generation siRNA platforms for rare metabolic disorders, leveraging Sanofi’s global reach and Alnylam’s delivery expertise.

Dicerna Therapeutics merged with AstraZeneca’s RNAi unit, creating a combined pipeline of 12 candidates and consolidating manufacturing capabilities.

The FDA granted approval to Alnylam’s OXL‑101, the second siRNA drug for hereditary transthyretin amyloidosis, expanding the class beyond first‑in‑class approvals.

The European Medicines Agency introduced an accelerated assessment pathway for RNAi medicines, cutting review timelines by up to 30% and encouraging earlier market entry.

Venture capital activity surged, with $1.2 bn raised in 2024 across 15 RNAi startups focused on novel delivery technologies and next‑gen target spaces.

Pfizer inaugurated a GMP‑grade RNAi manufacturing hub in Ireland, signaling major pharma’s commitment to scale production for upcoming launches.

Analyst Overview

The RNAi Therapeutics market remains highly attractive due to its proven clinical efficacy and expanding pipeline across oncology, rare diseases, and metabolic disorders. Competitive intensity is moderate; a few large biopharma firms dominate patented delivery platforms, while numerous niche players pursue differentiated targets, creating a balanced rivalry that encourages collaboration. The long‑term outlook is robust, with projected CAGR above 15% through 2035, driven by regulatory approvals and increasing payer acceptance. Innovation is centered on next‑generation lipid nanoparticles, conjugate chemistries, and gene‑editing hybrids, which promise higher potency and broader tissue access. Demand outpaces supply as more indications enter late‑stage trials, yet manufacturing capacity is tightening, prompting investment in scalable GMP facilities. Key risks include regulatory uncertainties around long‑term safety, potential pricing pressures, and supply‑chain disruptions for critical excipients. Stakeholders should monitor these variables while leveraging the favorable RNAi Therapeutics market outlook to guide portfolio and partnership decisions. Overall, the sector’s trajectory suggests sustained investment returns for early adopters.

11 items

1. Executive Summary

2. RNAi Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global RNAi Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global RNAi Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cardiovascular Disease

6.1.2. Genetic Disorder

6.1.3. Cancer

6.1.4. Other

6.2. Global RNAi Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Subcutaneous Injection

6.2.2. Intravenous Infusion

6.3. Global RNAi Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global RNAi Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global RNAi Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global RNAi Therapeutics Market Competition by Key Manufacturers

8.1. Global RNAi Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global RNAi Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alnylam Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Silence Therapeutics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Dicerna Pharmaceuticals (a Novo Nordisk company)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Arrowhead Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Roche

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ionis Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wave Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sirnaomics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CureVac

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global RNAi Therapeutics Market

Figure 4: Global RNAi Therapeutics Market: Drivers

Figure 5: Global RNAi Therapeutics Market: Challenges

Figure 6: Global RNAi Therapeutics Market: Trends

Figure 7: Global RNAi Therapeutics Market: Opportunity

Figure 8: Global RNAi Therapeutics Market: Restraint

Figure 9: Global RNAi Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global RNAi Therapeutics Market Value (USD Million) By Region

Figure 15: Global RNAi Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global RNAi Therapeutics Market Value (USD Million) By Region

Figure 23: Global RNAi Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global RNAi Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global RNAi Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global RNAi Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global RNAi Therapeutics Market Value (USD Million) By Region

Table 10: Global RNAi Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global RNAi Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global RNAi Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global RNAi Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 33: Alnylam Pharmaceuticals. Products Portfolio

Table 34: Silence Therapeutics Basic Information And Sales Area

Table 35: Silence Therapeutics. Products Portfolio

Table 36: Dicerna Pharmaceuticals (a Novo Nordisk company) Basic Information And Sales Area

Table 37: Dicerna Pharmaceuticals (a Novo Nordisk company). Products Portfolio

Table 38: Arrowhead Pharmaceuticals Basic Information And Sales Area

Table 39: Arrowhead Pharmaceuticals. Products Portfolio

Table 40: Roche Basic Information And Sales Area

Table 41: Roche. Products Portfolio

Table 42: Ionis Pharmaceuticals Basic Information And Sales Area

Table 43: Ionis Pharmaceuticals. Products Portfolio

Table 44: Wave Life Sciences Basic Information And Sales Area

Table 45: Wave Life Sciences. Products Portfolio

Table 46: Sirnaomics Basic Information And Sales Area

Table 47: Sirnaomics. Products Portfolio

Table 48: CureVac Basic Information And Sales Area

Table 49: CureVac. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global RNAi Therapeutics Market Value (USD Million) By Region

Table 55: Global RNAi Therapeutics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current RNAi Therapeutics market size?

The RNAi Therapeutics market size reached roughly USD 1.3 billion in 2023, driven by several FDA‑approved products and expanding pipelines across oncology, rare diseases, and metabolic disorders, according to leading industry analyses and increasing investor confidence in RNA interference platforms.

2. What is the projected growth forecast for the RNAi Therapeutics market?

Forecasts project the RNAi Therapeutics market to expand at a compound annual growth rate of 12.4% between 2024 and 2032, reaching approximately USD 4.5 billion by the end of the forecast horizon, propelled by new approvals and pipeline maturation.

3. Which factors are driving the market's expansion?

Key drivers include the validation of RNAi mechanisms in humans, scalable manufacturing technologies, strategic partnerships between biotech firms and big pharma, and reimbursement frameworks that recognize the value of disease‑modifying gene‑silencing therapies as well as growing prevalence of genetic disorders that lack effective treatments.

4. What are the main challenges hindering market adoption?

Challenges comprise delivery inefficiencies to target tissues, off‑target effects causing safety concerns, high development costs, and complex regulatory pathways that vary across jurisdictions, all of which can delay commercialization and increase pricing pressures while also requiring extensive clinical validation to satisfy payer expectations.

5. Which regions are leading in RNAi Therapeutics development and sales?

North America dominates in both R&D investment and market revenue, accounting for roughly 55% of global sales, while Europe follows with strong academic collaborations, and Asia‑Pacific is emerging rapidly due to government incentives and expanding biotech ecosystems.

6. Who are the top companies shaping the RNAi Therapeutics market?

Leading players include Alnylam Pharmaceuticals, Dicerna (now part of Novo Nordisk), Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics, each maintaining robust pipelines, strategic alliances, and multiple commercialized products that set industry benchmarks. Their extensive IP portfolios and global manufacturing capabilities further consolidate market leadership.

7. What future opportunities are emerging for RNAi Therapeutics?

Future opportunities involve expanding indications into cardiovascular and neurodegenerative diseases, leveraging next‑generation delivery vectors such as lipid nanoparticles, integrating RNAi with CRISPR‑based platforms, and tapping into personalized medicine models that match patients with bespoke gene‑silencing regimens.

8. How is technology influencing the market’s trajectory?

Advances in high‑throughput screening, artificial‑intelligence‑guided sequence optimization, and scalable GMP‑grade synthesis are shortening development timelines, reducing costs, and improving target specificity, thereby accelerating the future outlook for RNAi Therapeutics market growth. These innovations also enable combination therapies and broader patient access across diverse healthcare systems.

9. What is the regulatory landscape for RNAi Therapeutics?

Regulators in the US, EU, and Japan have established tailored guidance for oligonucleotide drugs, emphasizing rigorous non‑clinical safety packages and accelerated pathways for breakthrough indications, which together shape a nuanced but increasingly supportive environment for market entrants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

RNAi Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	10.78 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Alnylam Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals (a Novo Nordisk company); Arrowhead Pharmaceuticals; Roche; Ionis Pharmaceuticals; Wave Life Sciences; Sirnaomics; CureVac
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options